Therapeutic Mechanisms and Clinical Effects of Glucagon-like Peptide 1 Receptor Agonists in Nonalcoholic Fatty Liver Disease

被引：12
|
作者：
Lee, Han Ah [1 ]
Kim, Hwi Young [1 ]
机构：
[1] Ewha Womans Univ, Coll Med, Dept Internal Med, Seoul 07985, South Korea
来源：
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2023年 / 24卷 / 11期
基金：
新加坡国家研究基金会;
关键词：
nonalcoholic steatohepatitis; diabetes; liraglutide; semaglutide; tirzepatide; HEPATIC STEATOSIS; GLP-1; ANALOG; VITAMIN-E; DUAL GIP; LIRAGLUTIDE; METFORMIN; OBESITY; TRIAL; STEATOHEPATITIS; ADIPONECTIN;
D O I：
10.3390/ijms24119324
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Nonalcoholic fatty liver disease (NAFLD) can lead to liver fibrosis and cirrhosis. Recently, glucagon-like peptide 1 receptor agonists (GLP-1RAs), a class of drugs used to treat type 2 diabetes and obesity, have shown therapeutic effects against NAFLD. In addition to reducing blood glucose levels and body weight, GLP-1RAs are effective in improving the clinical, biochemical, and histological markers of hepatic steatosis, inflammation, and fibrosis in patients with NAFLD. Additionally, GLP-1RAs have a good safety profile with minor side effects, such as nausea and vomiting. Overall, GLP-1RAs show promise as a potential treatment for NAFLD, and further studies are required to determine their long-term safety and efficacy.
引用
收藏
页数：17
相关论文
共 50 条
  • [21] Glucagon-Like Peptide 1 Receptor Agonists in Psychiatry
    Himmerich, Hubertus
    Mcelroy, Susan L.
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2024, 44 (03) : 207 - 210
  • [22] Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
    Ussher, John R.
    Drucker, Daniel J.
    NATURE REVIEWS CARDIOLOGY, 2023, 20 (07) : 463 - 474
  • [23] Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
    John R. Ussher
    Daniel J. Drucker
    Nature Reviews Cardiology, 2023, 20 : 463 - 474
  • [24] Mechanisms of Cardiorenal Protection of Glucagon-Like Peptide-1 Receptor Agonists
    Tommerdahl, Kalie L.
    Nadeau, Kristen J.
    Bjornstad, Petter
    ADVANCES IN CHRONIC KIDNEY DISEASE, 2021, 28 (04) : 337 - 346
  • [25] Efficacy of Glucagon-Like Peptide-1 Analogs in Nonalcoholic Fatty Liver Disease: A Systematic Review
    Teshome, Getnet
    Ambachew, Sintayehu
    Fasil, Alebachew
    Abebe, Molla
    HEPATIC MEDICINE-EVIDENCE AND RESEARCH, 2020, 12 : 139 - 151
  • [26] Effect of glucagon-like peptide-1 receptor agonists on adipokine level of nonalcoholic fatty liver disease in rats fed high-fat diet
    Jin, Miaomiao
    Niu, Xiaohong
    Liu, Yan
    Zhang, Dong
    Yuan, Danni
    Shen, Huimin
    OPEN MEDICINE, 2020, 15 (01): : 689 - 696
  • [27] Correspondence to editorial on "Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis"
    Kim, Hayeon
    Park, Min Jeong
    Kim, Myeong Gyu
    Kim, Kyungim
    CLINICAL AND MOLECULAR HEPATOLOGY, 2024, 30 (04)
  • [28] Pentraxin 3 in patients with type 2 diabetes and nonalcoholic fatty liver disease: a promising treatment target for glucagon-like peptide-1 receptor agonists
    Patoulias, Dimitrios
    Kalogirou, Maria-Styliani
    Stavropoulos, Konstantinos
    Imprialos, Konstantinos
    Doumas, Michael
    POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ, 2019, 129 (09): : 648 - 649
  • [29] Use of thiazolidinediones and glucagon-like peptide-1 receptor agonists and the risk of non-alcoholic fatty liver disease
    Driessen, Johanna H. M.
    van Dalem, Judith
    Burden, Andrea M.
    Stehouwer, Coen D. A.
    Klungel, Olaf H.
    de Vries, Frank
    Brouwers, Martijn C. G. J.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 128 - 128
  • [30] Incorporating Glucagon-like Peptide-1 Receptor Agonists Into Clinical Practice
    Spellman, Craig W.
    JOURNAL OF THE AMERICAN OSTEOPATHIC ASSOCIATION, 2012, 112 (01): : S7 - S15
12345